1. An untargeted lipidomic analysis reveals depletion of several phospholipid classes in patients with familial hypercholesterolemia on treatment with Evolocumab®. (August 2022) Authors: Calcaterra, I.; Di Minno, A.; Anesi, A.; Cavalca, V.; Tripaldella, M.; Tremoli, E.; Iannuzzo Di Taranto, G.; Fortunato, G.; Di Minno, M.N.D. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Changes in carotid stiffness in patients with familial hypercholesterolemia treated with evolocumab®: A prospective cohort study. (December 2020) Authors: Calcaterra, I.; Gentile, M.; Iannuzzo, G.; Tripaldella, M.; Di Minno, A.; Forte, F.; Buonaiuto, A.; Di Taranto, M.D.; Rubba, P.; Di Minno, M.N.D. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Correlation between different LDL-R mutations and response to AB-PCSK9 therapy in a group of patient with genetic diagnosis of familial hypercholesterolemia. (December 2020) Authors: Buonaiuto, A.; Gentile, M.; Calcaterra, I.; Giacobbe, C.; Tripaldella, M.; Forte, F.; Di Minno, M.N.D.; Iannuzzo, G.; Fortunato, G.; Rubba, P. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗